Xilio Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Xilio Therapeutics, Inc. (XLO) reported Capital Expenditures Incurred but Not yet Paid of $10.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-12
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$9.00K.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $19.00K, a 93.49% decline year-over-year.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$8.00K.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $292.00K, a 1290.48% increase year-over-year.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $443.00K.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $19.00K, a 96.47% decline from fiscal 2021.
- Xilio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $539.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $19.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $443.00K 10-K · filed 2026-03-23 | |||
| 2025-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $284.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $292.00K 10-Q · filed 2026-05-12 | |||
| 2024-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $9.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-08 | |||
| 2023-03-31 | $310.00K 10-Q · filed 2024-05-14 | -$42.00K derived: sum of 2 quarters · filed 2024-05-14 | $175.00K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$135.00K derived: sum of 2 quarters · filed 2024-04-01 | $19.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $371.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $154.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $492.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $537.00K derived: sum of 2 quarters · filed 2023-03-02 | $290.00K derived: sum of 3 quarters · filed 2023-03-02 | $539.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$202.00K derived: sum of 2 quarters · filed 2022-11-09 | $47.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $249.00K 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $30.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |